GK
Therapeutic Areas
Enveric Biosciences Pipeline
| Drug | Indication | Phase |
|---|---|---|
| EB-003 | Difficult-to-Treat Mental Health Disorders (PTSD, Treatment-Resistant Depression, Generalized Anxiety) | Preclinical |
| EVM401 Series | Mental Health and Addiction (Opioid Withdrawal, ADHD, Anxiety, Depression, Substance Use Disorders) | Discovery |
| EVM301 Series | Neuropsychiatric Disorders | Discovery |
Leadership Team at Enveric Biosciences
JT
Joseph Tucker, Ph.D.
Chief Executive Officer, Director
PF
Peter Facchini, Ph.D.
Chief Innovation Officer
KC
Kevin Coveney, CPA
Chief Financial Officer
JH
Jillian Hagel
Vice President, Innovation
MD
Michael D. Webb
Board Chair
FP
Frank Pasqualone
Director, Chair of Compensation and Nominating Committees
MS
Marcus Schabacker, M.D., Ph.D.
Director, Chair of Science and Technology Committee
SD
Sheila DeWitt, Ph.D.
Director
MF
Maurizio Fava, M.D.
Scientific Advisor
SM
Stephen M. Stahl, M.D., Ph.D.
Scientific Advisor